Treatment of implant-associated infections with moxifloxacin: an animal study.
The efficacy of moxifloxacin in the treatment of an implant-associated infection by Staphylococcus aureus was compared with vancomycin in an animal study. The femoral medullary cavity of 36 Wistar rats was contaminated with S. aureus (ATCC 29213) and a metal device was implanted. After treatment for 14 days with moxifloxacin (2 x 10 mg/kg/day) or vancomycin (2 x 15 mg/kg/day), the bacterial counts (colony-forming units) in the periprosthetic bone, the soft tissue and the implant-associated biofilm were measured. Compared with the control group, moxifloxacin achieved a highly significant decrease in the microbial counts in the bone and soft tissue and in the biofilm (P<0.001). Moreover, the efficacy of moxifloxacin was significantly greater than that of vancomycin (P<0.01). Vancomycin did not reduce the microbial count significantly compared with the control group (P>0.05). The results justify further investigations of the treatment of implant-associated infections due to S. aureus with moxifloxacin.
Kalteis
Thomas
T
Department of Orthopedic Surgery, University of Regensburg, Kaiser-Karl V.-Allee 3, D-93077 Bad Abbach, Germany. thomas.kalteis@klinik.uni-regensburg.de
Beckmann
Johannes
J
Schröder
Hans-Jürgen
HJ
Schaumburger
Jens
J
Linde
Hans-Jörg
HJ
Lerch
Klaus
K
Lehn
Norbert
N
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use*; D018441:Biofilms / Q000187:drug effects; D024841:Fluoroquinolones; D020007:Implants, Experimental; D008297:Male; D000077266:Moxifloxacin; D010019:Osteomyelitis / Q000188:drug therapy*; D011804:Quinolines / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013203:Staphylococcal Infections / Q000188:drug therapy*; D014640:Vancomycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D014640:Vancomycin; D000077266:Moxifloxacin